A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets

Figure 4

TP53 mutational spectrum in 942 GC patients (a) and TP53 R175H mutation in MSK-IMPACT pan-cancer cohorts (b). PIK3CA mutational spectrum in 942 GC patients (c) and PIK3CA H1047R mutation in MSK-IMPACT pan-cancer cohorts (d).

(a)

(b)

(c)

(d)